Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Haleos Labs's Debt-to-EBITDA or its related term are showing as below:
BOM:540679'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.9 Med: 1.92 Max: 2.97
Current: 2.51
During the past 11 years, the highest Debt-to-EBITDA Ratio of Haleos Labs was 2.97. The lowest was 0.90. And the median was 1.92.
BOM:540679's Debt-to-EBITDA is ranked worse than 62.83% of 304
companies
in the Biotechnology industry
Industry Median: 1.255
vs BOM:540679: 2.51
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Haleos Labs Debt-to-EBITDA Related Terms
Haleos Labs Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540679 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Haleos Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Haleos Labs (BOM:540679) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haleos Labs. Over the past decade, Haleos Labs' Debt-to-EBITDA has ranged from 0.90 to 2.97. According to the industry distribution chart, Haleos Labs ranks #191 out of 304 companies in the Biotechnology industry, placing it in the top 62.8%.
Is Haleos Labs' Debt-to-EBITDA too high?
Haleos Labs' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 2.97. Based on the distribution chart, Haleos Labs ranks #191 out of 304 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Haleos Labs has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #191 out of 304 companies for Debt-to-EBITDA. This places Haleos Labs in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. Historically, Haleos Labs' own Debt-to-EBITDA has ranged from 0.90 to 2.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haleos Labs. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleos Labs's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (BOM:540679) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,153.70, compared to a current price of ₹1,497.20 — trading 29.8% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Haleos Labs' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Haleos Labs (BOM:540679), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (BOM:540679) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,497.20 is trading 29.8% above its estimated GF Value™ of ₹1,153.70.
GuruFocus considers Haleos Labs to be Modestly Overvalued.
Key valuation signals for BOM:540679:
Debt-to-EBITDA: 0.00
GF Value™: ₹1,153.70 vs. price of ₹1,497.20 (29.8% above fair value)
No single metric tells the full story. See the BOM:540679 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
71GF Score
Get the complete analysis for BOM:540679
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540679 has been successfully added to your 
